| A small percentage of the potential market would make AD04 a commercial success.
Adial Pharmaceuticals' Next Steps
Finalize plans to begin Phase 3 Clinical Trial.
Finalize Clinical Development Plan since receiving FDA feedback from EOP2 meeting
- Protocol design Aligned FDA endorsed adaptive trial design, biomarker stratification, and target population
- Endpoints Confirmed FDA validated primary endpoint of zero heavy drinking days during months 5-6
- Biomarker Strategy Affirmed FDA supported AG+ targeted therapy approach for biomarker-positive patients
- Statistical Framework Aligned FDA approved interim analyses, alpha control methodology, and DMC structure
- Phase 3 Cleared Regulatory alignment secured for advancement to registrational trial
Recently published FDA Policy Directive
- May reduce Pivotal Trial Burden from Two Studies to One
- Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04
Manufacturing drug product needed for clinical trial
Advancing Discussions with Potential Strategic Partners
- Phase 3 clinical program funding
- Commercialization of AD04 assuming a successful regulatory outcome
Grab Source And More Here: ADIL Website. ADIL Presentation. -----
And as I mentioned above, (Nasdaq: ADIL) has several potential catalysts on our radar. Check them out:
#1. ADIL Potential Catalyst - A Low Float Could Create An Environment Of Heightened Volatility Potential.
According to info from the Yahoo Finance website, ADIL has a very low float.
The website reports this profile to have roughly 858.25k shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides positive news towards the first part of 2026, could it help provide a breakout spark when paired with this volatility potential? -----
#2. ADIL Potential Catalyst - A Maxim Group Analyst Has Tagged ADIL With An $8 Target.
The Maxim Group has built one of the premier proprietary research platforms on Wall Street, with an emphasis on small-cap, micro-cap, and emerging growth companies.
Jason McCarthy, a senior analyst at Maxim Group covering the biotechnology sector, has suggested an $8.00 target for Adail Pharmaceuticals as of 3/2/26 according to published info on the company’s website.
With this $8.00 target, there could be upside potential of over 200% for ADIL from its closing valuation Monday. -----
#3. ADIL Potential Catalyst - A Recent FDA Policy Shift Could Create A Significant Impact (Potential Acceleration Towards NDA Submission).
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04
GLEN ALLEN, Va., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today highlighted recent U.S. Food and Drug Administration (FDA) policy direction described by FDA Commissioner Martin A. Makary, M.D., M.P.H., and Vinay Prasad, M.D., M.P.H., in a commentary published February 19, 2026, in The New England Journal of Medicine. In the article, FDA leadership outlined a shift in the agency’s default evidentiary posture under which, where scientifically appropriate, approval may be supported by one adequate and well-controlled clinical investigation plus confirmatory evidence, rather than the historic expectation of two independent pivotal studies.
This policy direction reflects a modernization of evidentiary standards, emphasizing trial quality and confirmatory support over the number of trials conducted, while preserving the FDA’s discretion to evaluate each development program on its scientific merits.
...
Cary Claiborne, President and Chief Executive Officer of Adial Pharmaceuticals, stated, “FDA’s policy direction confirming that, under appropriate scientific circumstances, approval may be supported by one adequate and well-controlled clinical investigation plus confirmatory evidence is a potentially transformative development for Adial. Historically, our Phase 3 strategy contemplated two pivotal trials, which represent the most expensive and time-intensive stage of drug development. If AD04 can ultimately be advanced under a one-study framework, the impact could be substantial — significantly lowering Phase 3 costs, improving overall capital efficiency, and accelerating our path toward NDA submission, without compromising agency standards. For a late-stage clinical program like AD04, that type of regulatory modernization meaningfully enhances the strategic and economic profile of the asset.”
...
Read the full article here. -----
#4. ADIL Potential Catalyst - An International PCT Patent Application Is Published (Aims To Extend Protection Of Core Assets Through 2045).
Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045
New patent based on treatment of populations identified to be particularly responsive to ondansetron treatment after examination of Adial’s clinical data and information
GLEN ALLEN, Va., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of the international patent application for AD04, filed in July 2024. AD04 is the Company’s lead investigational genetically targeted serotonin-3 receptor antagonist therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day). The patent, once granted, is expected to protect Adial’s core assets through at least 2045.
Cary Claiborne, President and Chief Executive Officer of Adial, commented, “As we continue to advance the AD04 program with planning for the next phase of our clinical program, the new patent application and its expected approval will extend protection of the core assets of Adial out to at least 2045. This application is the result of an extensive examination of data and information which occurred after Adial hired new patent counsel to bolster and leverage Adial’s intellectual property portfolio.”
Read the full article here. -----
#5. ADIL Potential Catalyst - Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing.
At 12:30PM EST Monday, Barchart was reporting ADIL to have several oversold leaning technical indicators.
These technicals could be signaling a healthy reversal is approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Here's the technicals to pay close attention to (as of 12:30PM EST Monday):
- 9-Day Relative Strength Index: 18.92%
- 14-Day Relative Strength Index: 18.34%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 14-Day Raw Stochastic %D: 16.84%
As the Raw Stochastic nears the 10% range and lower it may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely. -----
(Nasdaq: ADIL) Recap - 5 Potential Catalysts Hit Our Radar
#1. A Low Float Could Create An Environment Of Heightened Volatility Potential.
#2. A Maxim Group Analyst Has Tagged ADIL With An $8 Target.
#3. A Recent FDA Policy Shift Could Create A Significant Impact (Potential Acceleration Towards NDA Submission).
#4. An International PCT Patent Application Is Published (Aims To Extend Protection Of Core Assets Through 2045).
#5. Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing. -----
Coverage is now officially kicked-off on Adial Pharmaceuticals, Inc. (Nasdaq: ADIL).
Be on the lookout for updates coming your way shortly. Talk soon.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/02/2026 and ending on 03/03/2026 to publicly disseminate information about (ADIL:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). These Funds were part of the seventy seven thousand five hundred USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (ADIL:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/adil-snsyo/#details | 
0 التعليقات:
إرسال تعليق